Maravai LifeSciences Q1 revenue rises on higher CleanCap sales

Maravai Lifesciences Holdings

07/05/2026 21:19

Overview

US life science reagents provider's Q1 revenue rose 41% yr/yr, beating analyst expectations

Q1 adjusted EBITDA swung positive and beat analyst expectations

Company raised full-year 2026 revenue and EBITDA guidance

Outlook

Maravai raises 2026 revenue guidance to $205 mln-$215 mln from $200 mln-$210 mln

Company lifts 2026 adjusted EBITDA outlook to $30 mln-$32 mln from $18 mln-$20 mln

Result Drivers

TRILINK GROWTH - TriLink revenue rose 65% yr/yr, mainly due to $14.3 mln in high-volume CleanCap orders for commercial COVID vaccine programs

BASE BUSINESS DEMAND - TriLink base, non-COVID revenue grew 15% yr/yr, with strength in both Discovery and GMP consumables

OPERATIONAL EFFICIENCY - Co said focus on cost structure and operational efficiency contributed to EBITDA expansion and positive free cash flow

Company press release: ID:nBwPFt6ca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$65.80 mln
$53.05 mln (9 Analysts)
Q1 Net Loss
$6.40 mln
Q1 Adjusted EBITDA
Beat
$20.30 mln
$4.04 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 14.2% above its May 6 closing price of $3.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)